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Abstract
Background: Axillary lymph node dissection (ALND) has been the standard treatment of breast cancer axillary
staging in Indonesia. The limited facilities of radioisotope tracer and isosulfan or patent blue dye (PBD) have been
the major obstacles to perform sentinel node biopsy (SNB) in our country. We studied the application of 1%
methylene blue dye (MBD) alone for SNB to overcome the problem.
Methods: This prospective study enrolled 108 patients with suspicious malignant lesions or breast cancer stages
I–III. SNB was performed using 2–5 cc of 1% MBD and proceeded with ALND. The histopathology results of sentinel
nodes (SNs) were compared with axillary lymph nodes (ALNs) for diagnostic value assessments.
Results: There were 96 patients with invasive carcinoma from July 2012 to September 2014 who were included in
the final analysis. The median age was 50 (25–69) years, and the median pathological tumor size was 3 cm (1–10).
Identification rate of SNs was 91.7%, and the median number of the identified SNs was 2 (1–8). Sentinel node
metastasis was found in 53.4% cases and 89.4% of them were macrometastases. The negative predictive value
(NPV) of SNs to predict axillary metastasis was 90% (95% CI, 81–99%). There were no anaphylactic reactions, but we
found 2 cases with skin necrosis.
Conclusions: The application of 1% MBD as a single technique in breast cancer SNB has favorable identification
rates and predictive values. It can be used for axillary staging, but nevertheless the technique should be applied
with attention to the tumor size and grade to avoid false negative results.
Keywords: Sentinel node, Breast cancer, Axillary lymph node, Methylene blue dye
Background
Breast cancer is the most common malignancy, account-
ing for 31.2% of all cancers and 26.5% as the cause of
cancer death among women in our hospital [1]. In Asia-
Pacific region, 12% of breast cancer incidence rates and
17% of its death occur in Indonesia [2]. The information
of axillary lymph node (ALN) metastasis is one of the
most important prognostic factors in breast cancer
treatments. It is conventionally determined by axillary
lymph node dissection (ALND) [3, 4]. This procedure
gives morbidities such as lymphedema, loss of sensory,
limited mobility, and seroma formation which will de-
crease the quality of life [4–6]. Nowadays, breast cancer
treatments have moved towards conservation therapies,
and sentinel node biopsy (SNB) has been introduced as
a part of the minimal invasive breast surgery [3, 7].
Unfortunately, ALND is still the standard procedure for
axillary staging in Indonesia. The limitation to provide
sophisticated technologies for SNB has been our main-
stay issue.
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The work by Morton et al. [8] in cutaneous melanoma
was the turning point of the acceptance of the sentinel
node (SN) concept. It was soon adopted to breast cancer
patients by using isosulfan blue dye or radioisotope
tracer alone to find SNs. Initially, the reported identifica-
tion rates of SNs ranged between 65 and 98% and false
negative rates between 0 and 5% [9–12]. In developed
countries, the optimal technology for SNB uses isosulfan
or patent blue dye (PBD), preoperative lymphoscintigra-
phy, and radioisotope tracer, which are used as a single
or combination technique [9–13]. As an alternative to
these devices, several studies have been conducted to
validate 1% methylene blue dye (MBD) for SNB. Sim-
mons [14] was the first surgeon who reported the suc-
cessful application of 1% MBD in breast cancer SNB.
The other studies also supported its use because of the
favorable results in identification and false negative rates,
fewer allergic complications, and lower cost [15–22].
Limited access to PBD and radioisotope tracer is the
main problem to perform SNB in Indonesia. Not to
mention our geographic distribution of the population,
the availability and cost to provide nuclear medicines, or
gamma probes in every hospital have contributed to the
difficulty for administering SNB. Recently, we have
started to use 1% MBD alone, and the initial results from
24 patients were favorable with the identification rates of
95.8% [23]. As we have moved towards better breast
cancer care, it is important for us to conduct a study to
overcome the limitation to perform SNB. The primary
objective of the study is to evaluate the identification
rates and negative predictive value (NPV) of SNs to pre-
dict axillary metastasis by using 1% MBD alone.
Methods
Participants
In this study, 108 consecutive patients with diagnosis of
breast cancer or suspicious malignancy were enrolled
prospectively at Dharmais Cancer Hospital, Bogor City
General Hospital, and Mochtar Riady Comprehensive
Cancer Center (MRCCC) Siloam Hospital between July
2012 and September 2014. There were five surgeons par-
ticipating in the research. SJH, RK, and WG had more
than 5 years of experience, while BB and BA had more
than 3 years of experience in breast cancer surgery in-
cluding ALND. All surgeons had less than 10 cases in
performing MBD technique alone prior to the study. BB,
RK, and SJH were also the surgeons who were working
and undertaking SNB in the other participating hospitals
besides Dharmais Cancer Hospital. We included patients
with any tumor size (T) without palpable ALNs (cNo)
and had performed core needle or fine needle aspiration
(FNA) biopsy. Patients without final pathological results
of invasive breast cancer or had a pregnancy were
excluded from the study. The Institutional Review Board
at Dharmais Cancer Hospital approved the study, and all
patients were provided informed consent.
Sentinel node biopsy and axillary lymph node dissection
SNB was performed using 1% MBD. It was injected in a
subareolar or peritumoral area with the dose of 2 until
5 cc. We did a peritumoral injection in all cases with
previous excisional biopsy at the upper outer quadrant
of the breast or according to the surgeon’s preferences.
A breast massage was done for 5 min after the injection.
In a standard breast conserving or oncoplastic breast
conserving surgery (BCS), a separate incision in the
lower axillary hairline was made to find SNs before
lumpectomy or quadrantectomy. When the patients
underwent mastectomy, SNB was undertaken through
the same mastectomy incision before removing the
breast. Sentinel nodes were defined as blue nodes or
lymph nodes with a lymphatic blue channel. All proce-
dures proceeded to ALND levels I–II. Axillary lymph
node dissection level III was done when there were sus-
picious lymph node metastases at level II. If a frozen
section were available, it would be used to assess an in-
traoperative SN metastasis. Histopathological results of
all ALNs were collected after the surgery.
Pathological examination
The sentinel nodes were surgically removed at the be-
ginning of the surgical procedure and sent for a standard
pathological assessment or frozen-section examination if
available. The sentinel nodes were sectioned no thicker
than 2 mm and parallel to the long axis. An intraopera-
tive analysis was categorized to positive or negative for
metastases. The rest of SNs were formalin fixed and
paraffin sectioned with hematoxyline-eosin staining.
The tumors were histologically classified according to
the World Health Organization (WHO) Histological
Classification of Breast Tumors, and grading was defined
according to Elston and Ellis modification [24]. All spec-
imens were reviewed in Dharmais Cancer Hospital by
two pathologists (RIP and LS). Only 2 patients who
underwent surgery at MRCCC hospital were not
reviewed due to the patients’ preference and thus ana-
lyzed by using the original histopathology report from
the local pathologist. Molecular subtypes for invasive
cancer were classified as luminal A (ER+ and/or PR+,
HER2−, and histological grade either 1 or 2), luminal B
(ER+ and/or PR+, HER2+; or ER+ and/or PR+, HER2−
and grade 3), triple negative (ER−, PR−, HER2−), and
HER2+ (ER−, PR−, HER2+) [25].
The nodal involvement was classified according to the
6th edition of the American Joint Committee on Cancer
(AJCC) manual. Macrometastasis (MAC) is defined as
tumor deposits larger than 2 mm, micrometastasis
(MIC) if tumor deposits between 0.2 and 2.0 mm, and
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isolated tumor cells (ITCs) if there are cell clusters or a
single cell no larger than 0.2 mm. Serial sections and im-
munohistochemistry (IHC) for cytokeratin were per-
formed when there was some doubt to define ITCs. The
rest of ALNs were also examined in a similar manner. The
histopathology of SNs was compared to the final examin-
ation of ALNs for the presence of metastases [24, 26].
Statistical analysis
Descriptive data were presented in the table of fre-
quency. Sensitivity (Se), specificity (Sp), positive predict-
ive value (PPV), and negative predictive value (NPV)
were calculated using CATmaker. Diagnostic values
were reported with 95% confidence of interval (CI). We
used SPSS version 16.0 to manage the data.
Results
Patient characteristics
We prospectively enrolled 108 patients from July 2012 to
September 2014. Twelve patients with FNA biopsy result
of suspicious breast cancer were excluded because the fro-
zen section and final pathological results were not invasive
carcinoma. There were 87 (90.6%) patients from Dharmais
Cancer Hospital and 9 (9.4%) from the other hospitals. Of
the 96 patients who were included in the final analysis, the
median age was 50 years (range 25–69 years). There were
9 (9.4%) patients in stage I, 64 (66.7%) in stage II, and 23
(23.9%) in stage III. The median pathological tumor size
was 3 (1–10) cm. Invasive carcinoma of no special type
(NST) was the most common result which accounted for
71 (74%) patients and invasive lobular carcinoma (ILC) in
11 (11.5%) patients. We classified breast cancer molecular
profile based on IHC examination. Thirty-eight (39.6%)
patients were classified as luminal A breast cancer, 24
(25%) as luminal B, 10 (10.4%) as HER2+ type, and 24
(25%) as triple negative (TNBC). Mastectomy was the
most common surgical procedure which was done in 60
(62.5%), meanwhile BCS in 36 (37.5%) patients. Table 1
summarizes the characteristic of patients.
Sentinel node biopsy and pathological examination
We could identify SNs in 88 patients. Therefore, the SNs
identification rate was 91.7%. Peritumoral injections
were done in 29 (30.2%) and subareolar in 67 (69.8%)
cases. The median number of SNs that could be identi-
fied was 2 (1–8) and the median of ALNs was 11 (5–27).
In this group where SNs were identified, the number of
SNs without metastases was 41. Four of these patients
were found to have metastases in non-sentinel nodes
(NSNs), and so the total patients without lymph node
metastases were 37 (42%). There were 47 (53.4%) cases
with SN metastases and 42 (89.4%) of them had MAC.
The number of SN metastases which was only found in
1–2 SNs was 43 (91.5%), whereas 4 (8.5%) metastases
were identified in more than 2 SNs. We discovered 25
(53.2%) cases with additional metastatic deposits in NSNs.
Therefore, in 22 (46.8%) patients, the metastases only oc-
curred in SNs. Table 2 describes the cases with positive
SNs. The SNs detected metastases in 47 of 51 cases,
resulting in a Se of 92% (95% CI, 85–100%), and there
were 4 NSN metastases in the SN negative group which
resulted in a NPV of 90% (95% CI, 81–99%). All 4 cases
that failed to predict ALN metastases had a median patho-
logical tumor size of 4 cm, 2 patients in stage IIB and the
others were in stage IIIA. Three (75%) patients were grade
3 invasive carcinoma. Figure 1 and Table 3 show the re-
cruitment of patients and results of diagnostic value.
Table 4 describes the false negative patients
Unidentified sentinel nodes
The SNs could not be found in 8 patients. The median
age of the patients was 54 years old (range 36–67 years)
with the median tumor size of 2.8 (1.5–5.0) cm. There
were 2 (25%) grade 1, 3 (37.5%) grade 2, and 3 (37.5%)
grade 3 invasive carcinoma. Two (25%) patients had
Table 1 Patient characteristics (n = 96)
Patient characteristics Number Percentage
Age (years) Median (range) 96 50 (25–69)
Tumor size Median (range) 96 3 (1–10)
Pathology NST 71 74.0
ILC 11 11.4
Others 14 14.6
Molecular subtypes Luminal A 38 39.6
Luminal B 24 25.0
HER2 positive 10 10.4
Triple negative 24 25.0
Surgery Mastectomy 60 62.5
BCS 36 37.5
NST no special type, ILC invasive lobular carcinoma, BCS breast
conservation surgery
Table 2 Sentinel node characteristics of patients with positive
metastases (n = 47)
SN characteristic Number Percentage
Positive SN count 1–2 43 91.5
>2 4 8.5
Metastasis type Macrometastases 42 89.4
Micrometastases 5 10.6
Patients with SNs only
metastasis count
22 46.8
Patients with SN and
NSN metastasis count
25 53.2
SNs sentinel nodes, NSNs non-sentinel nodes
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lymph node metastases and the rest were negative. Table 5
describes the characteristic of the unidentified SN group.
Complications
Two patients experienced skin necrosis around the in-
jection site after 5 cc of peritumoral injection. They were
mastectomies cases one of whom had a breast
reconstruction. These patients successfully underwent
conservative wound treatment. We found no systemic
anaphylactic reactions among all patients.
Discussion
The paradigm of early breast cancer management has
changed toward conservation treatments, and SNB has
replaced ALND in terms of axillary staging [27, 28]. In
comparison with developed countries, the majority of
breast cancer cases in our country are in locally ad-
vanced stages [29]. This is the reason why ALND has
become a common practice among our surgeons. Now-
adays, we have been expecting to treat patients in early
stages since the improvement in our national health care
insurance and this condition will motivate us to promote
SNB. Although the standard for lymphatic mapping sup-
ports the combination technique [13, 30], limited access
to radioisotope tracers, PBD, and nuclear medicine
facilities have become our obstacles. Our population is
distributed across islands and not every hospital has
sophisticated technologies for SNB. Therefore, we try to
overcome this problem by applying 1% MBD alone for
SN identification.
The issue of PBD limitation was solved by several
authors with the utilization of 1% MBD which had favor-
able results [17, 21, 31]. The identification rate of 92%
from our research was acceptable when it was compared
with the other studies that used MBD [14–17, 19–21].
Another research which supported our result was con-
firmed by Liu et al. in their randomized controlled study
in cutaneous melanoma. They found that MBD was as
effective as isosulfan blue dye to identify SNs [32]. The
median SN number, which was 2 nodes from our study,
was equal with the studies that suggested to find 2 until
3 SNs to minimize the false negative rate [33–37].
In the identified SN group, 42% of the cases were
lymph node negative for metastases. It means that there
were many cases which were not supposed to receive
ALND and we could have saved a lot of patients from
having the risk of lymphedema and other morbidities.
We believe if our surgeons can apply this SNB technique
instead of routine ALND, we will make a better quality
of life after the surgery and overall reduce the cost of
108 patients
96 patients
8 SNs not identified88 SNs Identified
41 SNs Mets (-)
37 NSNs Mets (-)
4 NSNs Mets (+)
4 Axillary Mets (+)
47 SNs Mets (+)
47 Axillary Mets (+)
Excluded 12 patients
12 patients with primary tumor that 
were not invasive breast cancer
Fig. 1 Patients flowchart for recruitment and SN assessment to
predict axillary metastasis. SNs sentinel nodes, NSNs non-sentinel
nodes, Mets metastasis
Table 3 Diagnostic value of sentinel nodes (n = 88)









Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative
predictive value, CI confidence interval
Table 4 Characteristics of patients with false negative SN (n = 4)
Patient characteristics Number Percentage
Age (years) Median (range) 4 44 (35–59)
Tumor size Median (range) 4 4.0 (3.0–6.0)
Pathology NST 4 100.0
Molecular subtypes Luminal B 3 75.0
Triple negative 1 25.0
Tumor grade 2 1 25.0
3 3 75.0
NST no special type
Table 5 Characteristics of patients with unidentified SN (n = 8)
Patient characteristics Number Percentage
Age (years) Median (range) 8 54 (36–67)
Tumor size Median (range) 8 2.8 (1.5–5.0)
Pathology NST 7 87.5
Ca with medullary feature 1 12.5
Molecular subtypes Luminal A 4 50.0
HER2 positive 2 25.0
Triple negative 2 25.0
Tumor grade 1 2 25.0
2 3 37.5
3 3 37.5
Metastases in LN Positive 2 25.0
Negative 6 75.0
NST no special type, Ca carcinoma, LN lymph node
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breast cancer treatment in Indonesia and its associated
surgical morbidities.
The next important findings from our study were the
facts that 53% of metastatic foci were found in SNs and
nearly half (47%) of them were only confined in SNs.
The early publications of SNB in breast cancer have also
reported that approximately 50% patients with SN me-
tastases did not have positive NSNs [38, 39]. In this case,
the utility of a nomogram to predict NSN metastases
[40–43] would become a valuable tool for us.
The Z0011, IBCSG 23-01, and AMAROS studies have
given new perspectives to omit ALND after positive SNs
[44–46]. According to the studies, patients with a small-
sized tumor, plans for BCS, and whole breast radiation
are the suitable indications. These selection criteria did
not match with the majority of our patient characteris-
tics because it had been shown in this study that we had
bigger median tumor size, 24% cases were in stage III,
89% MAC in SNs, and mastectomy was more common
than BCS. As we had 91% patients with 1 until 2 metas-
tases in SNs, the POSNOC trial is expected to give us a
better evidence for omitting ALND after positive SNs
[47], particularly in mastectomy which represents the
majority of our cases.
The reported NPV in this study was 90%, and a ran-
domized study from Canavese et al. nearly had the same
result (91.1%) [48]. We realized that our NPV was lower
than the other studies (92.3 and 96.1%) [49, 50]. It might
have been due to the 4 false negative cases which had
bigger median tumor size (4 cm) and higher tumor
grade (75% in grade 3). So, there were possibilities that
tumor size more than 3 cm and high grade tumors had
higher risks of volume nodal metastases and blockage of
the lymphatic system to SNs and alternates to false SNs
[48, 51]. However, when we analyzed separately by ex-
cluding stage III patients (data not shown), the NPV
would be 95% (95% CI, 80–100%). Therefore, surgeons
must be cautious when performing SNB with MBD
alone in a patient with grade 3 and more than 3 cm
tumor size. Under these circumstances, looking for add-
itional non blue suspicious lymph nodes is suggested to
minimize false negative result.
In this study, SNs could not be found in 8 patients.
There are some related factors with the failures to find
SNs. The age, body mass index (BMI), tumor size, loca-
tion, grade, type of previous biopsy, SNB technique, and
surgeon’s experience have been reported in literatures as
the factors that influence SN identification [52–54]. The
median age of the unidentified SN group was 54 years
and this older condition could have been one of the fac-
tors which accounted for the unsuccessful identification
in the final result. The increased fatty tissue in the breast
among older patients may decrease lymphatic flow and
failures to identify SNs [52, 53].
The surgeon’s experience is another important factor
for localizing SNs, especially if blue dye alone is used as
the method of choice. Some literatures have explained
that identification of SNs will be reduced by less experi-
enced surgeons and the use of blue dye alone technique
[53, 54]. Our failure to find SNs might have been ex-
plained by these factors as well because in this study, the
application of MBD alone was a relatively new technique
for us and we did not have many experiences regarding
this technique prior to the study.
Higher tumor grade has been known as a negative fac-
tor for SN identification in univariate analysis [53]. In
our result, grades 2 and 3 tumors constituted about 75%
of the cases. Although tumor grade has not been proven
as an independent factor for the failure [53], we think it
could have contributed to the negative finding in our
study.
We experienced two skin necroses around the injec-
tion site. Local skin irritation or necrosis after MBD
injection was reported by other authors [22, 55]. The
toxic effects are due to the formation of aldehydes and a
reduction in oxidation products which initiate inflamma-
tory reactions [56]. Although we were not really sure if
the skin necrosis was caused by MBD or skin flap necro-
sis after mastectomy, we decided to lower the dose of in-
jection until 2 cc and we did not have skin necrosis
thereafter. We did not find anaphylactic reactions in our
cases. The incidence of allergic reactions following PBD
was between 0.06 and 2.7% [56]. Whereas anaphylactic
reactions following MBD injection was very rare, there
were several related serious effects after intrauterine in-
jection [57–60] and pulmonary edema had also been re-
ported after breast cancer SNB in two series [61, 62].
Although MBD can be used safely for lymphatic map-
ping because of its very rare effects in allergic reactions,
we suggest that the operating team should be aware and
prepared for the potential anaphylactic reactions of
MBD that could happen.
This study had several limitations. First, we only in-
cluded clinically node negative patients but we did not
perform ALN biopsy if the axillary ultrasound found sus-
picious lymph nodes. Ultrasound-guided axillary lymph
node biopsy will select patients with true negative lymph
nodes before surgery. Second, blue nodes or non-blue
nodes with lymphatic blue channels were the only criteria
for SNs. We did not try to find the non-blue suspicious
nodes as SNs. These could have reduced our NPV results,
especially in cases with high grade and bigger tumor size
that could have alternated MBD into the false SNs.
Conclusions
This study has proven that SNB in breast cancer can be
performed with 1% MBD alone. It can be done in clin-
ical settings with limited access to perform the standard
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combination technique or when PBD is not available.
The important factors that should be considered are the
following: first, in high grade and bigger tumor size, sur-
geons must not be satisfied when they only find the blue
nodes. The non-blue suspicious lymph nodes must be
searched in order to reduce false negative results. Sec-
ond, a better understanding of the SN anatomic location
in the axilla is the key point to increase the identification
rate when applying MBD alone technique.
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